Sulfatide inhibits α-galactosylceramide presentation by dendritic cells

International Immunology

Volumn 24, Issue 2, 2012, Pages 129-136

  Kanamori, Mitsuhiro ^a   Tasumi, Yusuke ^a   Iyoda, Tomonori ^a,b   Ushida, Maki ^a,b   Inaba, Kayo ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b Core Research of Evolutional Science and Technology ^*  (Japan)

Author keywords

CD1d; Dendritic cell; NKT cell; GalCer

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; CD40 LIGAND; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 12P70; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SULFATIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ARTICLE; CELL ACTIVATION; CELL ACTIVITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; T LYMPHOCYTE; UPREGULATION;

EID: 84856588122     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxr108     Document Type: Article

References (43)

1. Svennerholm, L., Bostrom, K., Fredman, P., Jungbjer, B., Mansson, J. E. and Rynmark, B. M. 1992. Membrane lipids of human peripheral nerve and spinal cord. Biochim. Biophys. Acta 1128:1.
2. Tadano-Aritomi, K., Hikita, T., Fujimoto, H., Suzuki, K., Motegi, K. and Ishizuka, I. 2000. Kidney lipids in galactosylceramide synthase-deficient mice. Absence of galactosylsulfatide and compensatory increase in more polar sulfoglycolipids. J. Lipid Res. 41:1237.
3. Buschard, K., Blomqvist, M., Osterbye, T. and Fredman, P. 2005. Involvement of sulfatide in beta cells and type 1 and type 2 diabetes. Diabetologia 48:1957.
4. Buschard, K., Josefsen, K., Horn, T. and Fredman, P. 1993. Sulphatide and sulphatide antibodies in insulin-dependent diabetes mellitus. Lancet 342:840.
5. Andersson, K., Buschard, K., Fredman, P. et al. 2002. Patients with insulin-dependent diabetes but not those with non-insulindependent diabetes have anti-sulfatide antibodies as determined with a new ELISA assay. Autoimmunity 35:463.
6. Morichika, H., Hamanaka, Y., Tai, T. and Ishizuka, I. 1996. Sulfatides as a predictive factor of lymph node metastasis in patients with colorectal adenocarcinoma. Cancer 78:43.
7. Jahng, A., Maricic, I., Aguilera, C., Cardell, S., Halder, R. C. and Kumar, V. 2004. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J. Exp. Med. 199:947.
8. Kanter, J. L., Narayana, S., Ho, P. P. et al. 2006. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat. Med. 12:138.
9. Zajonc, D. M., Maricic, I., Wu, D. et al. 2005. Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J. Exp. Med. 202:1517.
10. Lantz, O. and Bendelac, A. 1994. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8-T cells in mice and humans. J. Exp. Med. 180:1097.
11. Godfrey, D. I., MacDonald, H. R., Kronenberg, M., Smyth, M. J. and Van Kaer, L. 2004. NKT cells: what's in a name? Nat. Rev. Immunol. 4:231.
12. Arrenberg, P., Halder, R., Dai, Y., Maricic, I. and Kumar, V. 2010. Oligoclonality and innate-like features in the TCR repertoire of type II NKT cells reactive to a beta-linked self-glycolipid. Proc. Natl Acad. Sci. USA 107:10984.
13. Blomqvist, M., Rhost, S., Teneberg, S. et al. 2009. Multiple tissuespecific isoforms of sulfatide activate CD1d-restricted type II NKT cells. Eur. J. Immunol. 39:1726.
14. Jeon, S. B., Yoon, H. J., Park, S. H., Kim, I. H. and Park, E. J. 2008. Sulfatide, a major lipid component of myelin sheath, activates inflammatory responses as an endogenous stimulator in brainresident immune cells. J. Immunol. 181:8077.
15. Popovic, Z. V., Sandhoff, R., Sijmonsma, T. P. et al. 2007. Sulfated glycosphingolipid as mediator of phagocytosis: SM4s enhances apoptotic cell clearance and modulates macrophage activity. J. Immunol. 179:6770.
16. Arrenberg, P., Maricic, I. and Kumar, V. 2011. Sulfatide-mediated activation of type II natural killer T cells prevents hepatic ischemic reperfusion injury in mice. Gastroenterology 140:646.
17. Halder, R. C., Aguilera, C., Maricic, I. and Kumar, V. 2007. Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J. Clin. Invest. 117:2302.
18. Ambrosino, E., Terabe, M., Halder, R. C. et al. 2007. Crossregulation between type I and type II NKTcells in regulating tumor immunity: a new immunoregulatory axis. J. Immunol. 179:5126.
19. Terabe, M., Matsui, S., Park, J. M. et al. 2003. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198:1741.
20. Fuss, I. J., Heller, F., Boirivant, M. et al. 2004. Nonclassical CD1drestricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J. Clin. Invest. 113:1490.
21. Bovin, L. F., Fredman, P., Mansson, J. E., Buschard, K. and Bendtzen, K. 1999. In vitro production of cytokines is influenced by sulfatide and its precursor galactosylceramide. FEBS Lett. 455:339.
22. Roeske-Nielsen, A., Fredman, P., Mansson, J. E., Bendtzen, K. and Buschard, K. 2004. Beta-galactosylceramide increases and sulfatide decreases cytokine and chemokine production in whole blood cells. Immunol. Lett. 91:205.
23. Roark, J. H., Park, S. H., Jayawardena, J., Kavita, U., Shannon, M. and Bendelac, A. 1998. CD1.1 expression by mouse antigenpresenting cells and marginal zone B cells. J. Immunol. 160:3121.
24. Kawano, T., Cui, J., Koezuka, Y. et al. 1997. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278:1626.
25. Spada, F. M., Koezuka, Y. and Porcelli, S. A. 1998. CD1drestricted recognition of synthetic glycolipid antigens by human natural killer T cells. J. Exp. Med. 188:1529.
26. Iyoda, T., Ushida, M., Kimura, Y. et al. 2010. Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation. Int. Immunol. 22:905.
27. Iyoda, T., Shimoyama, S., Liu, K. et al. 2002. The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J. Exp. Med. 195:1289.
28. Brigl, M. and Brenner, M. B. 2004. CD1: antigen presentation and T cell function. Annu. Rev. Immunol. 22:817.
29. Bezbradica, J. S., Stanic, A. K., Matsuki, N. et al. 2005. Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J. Immunol. 174:4696.
30. Bai, L., Sagiv, Y., Liu, Y. et al. 2009. Lysosomal recycling terminates CD1d-mediated presentation of short and polyunsaturated variants of the NKT cell lipid antigen alphaGalCer. Proc. Natl Acad. Sci. USA 106:10254.
31. Im, J. S., Arora, P., Bricard, G. et al. 2009. Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation. Immunity 30:888.
32. Roy, K. C., Maricic, I., Khurana, A., Smith, T. R., Halder, R. C. and Kumar, V. 2008. Involvement of secretory and endosomal compartments in presentation of an exogenous self-glycolipid to type II NKT cells. J. Immunol. 180:2942.
33. Joyee, A. G., Uzonna, J. and Yang, X. 2010. Invariant NKT cells preferentially modulate the function of CD8 alpha+ dendritic cell subset in inducing type 1 immunity against infection. J. Immunol. 184:2095.
34. Gelin, C., Sloma, I., Charron, D. and Mooney, N. 2009. Regulation of MHC II and CD1 antigen presentation: from ubiquity to security. J. Leukoc. Biol. 85:215.
35. Brigl, M., Bry, L., Kent, S. C., Gumperz, J. E. and Brenner, M. B. 2003. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat. Immunol. 4:1230.
36. Swann, J., Crowe, N. Y., Hayakawa, Y., Godfrey, D. I. and Smyth, M. J. 2004. Regulation of antitumour immunity by CD1d-restricted NKT cells. Immunol. Cell Biol. 82:323.
37. Shi, F. D. and Van Kaer, L. 2006. Reciprocal regulation between natural killer cells and autoreactive T cells. Nat. Rev. Immunol. 6:751.
38. Stanic, A. K., Shashidharamurthy, R., Bezbradica, J. S. et al. 2003. Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural T(iNKT) cell receptor [corrected]. J. Immunol. 171:4539.
39. Burdin, N., Brossay, L., Koezuka, Y. et al. 1998. Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes. J. Immunol. 161:3271.
40. Ernst, W. A., Maher, J., Cho, S. et al. 1998. Molecular interaction of CD1b with lipoglycan antigens. Immunity 8:331.
41. Moody, D. B., Zajonc, D. M. and Wilson, I. A. 2005. Anatomy of CD1-lipid antigen complexes. Nat. Rev. Immunol. 5:387.
42. Colombo, M. P. and Trinchieri, G. 2002. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13:155.
43. Furumoto, K., Arii, S., Yamasaki, S. et al. 2000. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses. Int. J. Cancer 87:665.